Peter JH Scott, PhD

 Peter J. Scott
Legacy Professor of Radiology
Associate Chair, Basic Science Research
Program Assistant, Cyclotron Facility, Department of Radiology
Professor of Pharmacology, Medical School
Professor of Medicinal Chemistry, College of Pharmacy
Email:
[email protected]
Available to mentor
Peter JH Scott, PhD
Peter J. Scott
Professor
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications

  • Manage Your Profile

    • Qualifications
    • PhD
      University of Durham, Durham, United Kingdom
      2001 - 2005
    • BSc
      Loughborough University, Loughborough, Leicestershire,, United Kingdom
      1997 - 2001

    Center Memberships
    • Center Member
      Rogel Cancer Center
    • Center Member
      Biosciences Initiative

    Research Overview

    - Developing new methods for radiolabeling bioactive molecules.
    - Design and synthesis of new radiotracers for PET imaging of CNS disorders such as Alzheimer's disease.
    - cGMP radiopharmaceutical manufacture.
    - Implementation of new technology for radiochemistry and PET imaging, including automation, artificial intelligence and the internet of things.
    .

    Recent Publications

     See All Publications
    • Journal Article
      Highlight selection of radiochemistry and radiopharmacy developments by editorial board
      Kiss OC, Penuelas I, Rey A, Yang Z, Gillings N, Pillai A, Cazzola E, Reilly RM, Taddei C, Liu J, van Dam M, Furumoto S, Zhang J, Bernardes ES, Lodi F, Deuther-Conrad W, Huang YY, Lagebo YJ, Ekoume FP, Avila-Rodriguez MA, Summers B, Elrefaei A, Salgueiro M, Ramogida CF, Scott PJH. Ejnmmi Radiopharmacy and Chemistry, 2026 Dec 1; 11 (1): DOI:10.1186/s41181-026-00443-1
    • Journal Article
      Automated clinical production, dosimetry estimates and preclinical safety considerations for clinical translation of a SOAT1-targeted PET imaging agent
      Kaup G, Kaur T, Henderson BD, Winton WP, Hill JR, Raffel DM, Stauff J, Wong KK, Brooks AF, Shao X, Hammer GD, Viglianti BL, Scott PJH. Nuclear Medicine and Biology, 2026 Nov 1; 162-163: DOI:10.1016/j.nucmedbio.2026.109681
    • Journal Article
      Recent advances in [11C]HCN radiochemistry and applications to (pre)clinical PET imaging
      McCarthy CJ, Scott PJH. Nuclear Medicine and Biology, 2026 Nov 1; 162-163: DOI:10.1016/j.nucmedbio.2026.109682
    • Journal Article
      Reply to Zoghbi and Innis: Clarifying the cellular basis of GPR84-PET signal in neuroinflammation
      Kalita M, Kuo RC, Reyes ST, Scott PJH, Milligan G, James ML. Proceedings of the National Academy of Sciences of the United States of America, 2026 Oct 6; 123 (40): DOI:10.1073/pnas.2623658123
      PMID: 42804626
    • Journal Article
      White matter lesions disrupt cholinergic pathways important for cognition in Parkinson’s disease
      Carli G, Brown T, Michalakis F, Biddix A, Roytman S, Vangel R, Van Hout A, Kanel P, Scott PJH, Albin RL, Bohnen NI. Brain, 2026 Oct 1; 149 (10): 3495 - 3508. DOI:10.1093/brain/awag172
      PMID: 42117428
    • Journal Article
      Copper-mediated 77Br, 125I, and 211At radiohalogenation of aryl thianthrenium salts using visible light
      Martorano P, Gundam SR, Qian S, McCarthy CJ, Cingoranelli S, Cheng K, Webb EW, Bowden GD, Lee HB, Ellison P, Scott PJH, Mach RH, Makvandi M, Lee HS, Wright JS. npj Imaging, 2026 Sep 30; DOI:10.1038/s44303-026-00194-3
    • Journal Article
      Functionalization of indoles using a DABCO-Meldrum's acid reagent
      Allen AC, Kim H, Hubers D, Kim I, Han G, Scott PJH, Witek JA. Tetrahedron Letters, 2026 Sep 1; 182: DOI:10.1016/j.tetlet.2026.156154
    • Journal Article
      Assessment of PET drug adverse events in the U.S. since the implementation of 21 CFR part 212.
      Dakanali M, VanBrocklin HF, Zigler SS, Scott PJH. EJNMMI Radiopharm Chem, 2026 Jul 23; 11 (1): DOI:10.1186/s41181-026-00482-8
      PMID: PMC13680347

    Featured News & Stories
    Department News

    Atonco and University of Michigan Announce Collaboration on Phase 1-2a Clinical Study of ATO-101™

    Bladder cancer ranks among the most common cancers, with limited success from current therapies like BCG. Atonco’s ATO-101™, a targeted radiopharmaceutical using astatine-211, will be tested in a Phase 1–2a trial led by Drs. Viglianti and Scott to assess its precision and safety. This study represents a promising step toward more effective, less invasive treatments for bladder cancer.
    Department News

    Faculty Promotions (effective September 1, 2023)

    Faculty Promotions (effective September 1, 2023) at the U-M Medical School Department of Pharmacology